Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.
Latest funding size
Time since last funding
|BB Biotech Ventures, Invus, Abu Dhabi Investment Authority, Sequoia Capital China, AstraZeneca, Fidelity Management and Research Company, Julius Baer Group, RA Capital Management, Biomedical Advanced Research and Development Authority (BARDA), Alexandria Venture Investments, Viking Global Investors, Alexion Pharmaceuticals, Flagship Ventures, Wellington Management, EDBI, Pictet Private Equity Investors S.A., ArrowMark Partners, DARPA, Bill & Melinda Gates Foundation|
|Y, 2015||May, 2017|
Drugs in Development